Back to top
more

Immunic (IMUX)

(Delayed Data from NSDQ)

$1.30 USD

1.30
137,135

+0.02 (1.17%)

Updated May 15, 2024 04:00 PM ET

After-Market: $1.29 -0.01 (-0.39%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IMUX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Immunic, Inc. [IMUX]

Reports for Purchase

Showing records 101 - 120 ( 213 total )

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

07/02/2021

Company Report

Pages: 5

IMU-838 Multiple Sclerosis Clinical Program Defined; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

07/02/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

07/02/2021

Company Report

Pages: 7

Immunic Advances to Phase 3 in RRMS and Explores Oppy in Progressive MS

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

07/02/2021

Company Report

Pages: 9

FDA Cleared RRMS Phase 3s and PMS Phase 2, Dosing Starts in H2:21

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

07/01/2021

Company Report

Pages: 6

IMU-935 Shows Encouraging SAD PK PD Data in Healthys. MAD Data in 2H2021

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

05/10/2021

Company Report

Pages: 5

Multiple Sclerosis Trial Starting; COVID-19 Plan Halted; Lowering PT to $40

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

05/10/2021

Company Report

Pages: 7

Q1; Pipeline Progress; Initiation of RRMS Ph3 Anticipated in H2:21

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

05/07/2021

Company Report

Pages: 5

1Q21 Update- Pullback Is Temporary, Don''t Lose Sight of Key Value Drivers

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

05/07/2021

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

04/16/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

04/16/2021

Company Report

Pages: 7

Sub-trial Data Support 30mg Dose Selection for IMMU-838/RRMS Pivotal Phase 3s

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

04/15/2021

Company Report

Pages: 5

Phase 2 Multiple Sclerosis Studies Completed, Phase 3 to Initiate in 2H21

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

04/12/2021

Daily Note

Pages: 12

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

04/11/2021

Industry Report

Pages: 16

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

04/09/2021

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

04/08/2021

Company Report

Pages: 8

KOL Call Highlights PSC Unmet Need & Potential Pivotal Study Endpoints

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

04/07/2021

Company Report

Pages: 7

Piecing Together The Opportunity in PSC; KOL Call on Thursday, April 8

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

04/07/2021

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

03/03/2021

Daily Note

Pages: 4

Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Immunic, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

03/02/2021

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party